GEN Exclusives

More »

GEN News Highlights

More »
Apr 9, 2008

Harvard Allies with Merck & Co. on Osteoporosis Research

  • Harvard University’s Office of Technology Development and Merck & Co. have agreed to collaborate to further research on osteoporosis. The parnters expect to discover molecules with the potential for drug development.

    Under the multiyear license and research agreement, Merck & Co. Merck will fund ongoing research in the laboratory of Laurie Glimcher, M.D., the Irene Heinz Given professor of immunology at Harvard School of Public Health and a professor of medicine at Harvard Medical School.

    Dr. Glimcher’s research has reportedly elucidated the role of a recently identified regulator in adult bone formation. An adaptor protein regulates the growth of cells called osteoblasts that are responsible for bone formation, she says. Building on this and subsequent discoveries, the Merck-Harvard collaboration will seek to identify compounds that can effectively intervene in this pathway to enhance the growth of osteoblasts in humans with the goal of strengthening bone and staving off osteoporosis.

    In accordance with the agreement, Merck will also be granted a license to certain specific molecules that may arise from this project.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

New NIH Budget Proposal Leaves Many Confused and Unsettled

Do you think that using the so-called “mandatory budget funds” to pay for the proposed $825 million increase, as well as $1 billion of the NIH’s existing budget is a good idea?

More »